{"title":"From Immune Reshaping to Functional Cure: Translational Considerations for NK Cell Therapy in HBV.","authors":"Long Xu, Yan Wang, Guiqiang Wang","doi":"10.3350/cmh.2025.1463","DOIUrl":"https://doi.org/10.3350/cmh.2025.1463","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Call for More Efforts to Incorporate Liver in the Metabolic Health Framework.","authors":"Shadi Zerehpoosh, Ziyan Pan, Mohammed Eslam","doi":"10.3350/cmh.2025.1427","DOIUrl":"https://doi.org/10.3350/cmh.2025.1427","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extending MET-TRIB3 Axis Research in Hepatocellular Carcinoma: Immune Contexture and Patient Subgroups.","authors":"Lei Wu, Ning Liu, Pengyuan Song, Meili Sun","doi":"10.3350/cmh.2025.1357","DOIUrl":"https://doi.org/10.3350/cmh.2025.1357","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New Insights into Antibody-Mediated NK Cell Immunity in Hepatitis B: Editorial on \"Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to HBV outcomes\".","authors":"Zuzana Macek Jilkova, Caroline Aspord","doi":"10.3350/cmh.2026.0025","DOIUrl":"https://doi.org/10.3350/cmh.2026.0025","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sherlot Juan Song, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
{"title":"A cost-effectiveness evaluation framework for treatment for metabolic dysfunction-associated steatohepatitis: potential and concerns.","authors":"Sherlot Juan Song, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip","doi":"10.3350/cmh.2025.1459","DOIUrl":"https://doi.org/10.3350/cmh.2025.1459","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatitis B virus (HBV) remains a major cause of chronic liver diseases, especially in the Asia-Pacific region. In recent decades, coinfection with hepatitis C virus (HCV) and coexistence with metabolic dysfunction-associated steatotic liver disease (MASLD) have emerged as significant clinical concerns among HBV-infected subjects. Although global HBV vaccination programs and curative therapies for HCV have led to a marked decline in HBV/HCV coinfection, MASLD is rapidly becoming the predominant comorbidity due to the global surge in metabolic risk factors. HBV/HCV coinfection typically results in more severe liver damage, with unique challenges in antiviral treatment and risk of HBV reactivation post-HCV clearance. In contrast, HBV/MASLD overlap demonstrates complex metabolic-viral interactions that may influence viral replication, hepatitis B surface antigen seroclearance, fibrosis progression, and risk of hepatocellular carcinoma. This review critically compares the epidemiology, clinical outcomes, and management strategies of HBV patients with concurrent HCV or MASLD, while addressing current research gaps and proposing directions for future investigations.
{"title":"Treatment Strategies for Patients with HBV Infection Coexisting with HCV or MASLD.","authors":"Chieh Liu, Yi-Fen Shih, Chun-Jen Liu","doi":"10.3350/cmh.2025.1227","DOIUrl":"https://doi.org/10.3350/cmh.2025.1227","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) remains a major cause of chronic liver diseases, especially in the Asia-Pacific region. In recent decades, coinfection with hepatitis C virus (HCV) and coexistence with metabolic dysfunction-associated steatotic liver disease (MASLD) have emerged as significant clinical concerns among HBV-infected subjects. Although global HBV vaccination programs and curative therapies for HCV have led to a marked decline in HBV/HCV coinfection, MASLD is rapidly becoming the predominant comorbidity due to the global surge in metabolic risk factors. HBV/HCV coinfection typically results in more severe liver damage, with unique challenges in antiviral treatment and risk of HBV reactivation post-HCV clearance. In contrast, HBV/MASLD overlap demonstrates complex metabolic-viral interactions that may influence viral replication, hepatitis B surface antigen seroclearance, fibrosis progression, and risk of hepatocellular carcinoma. This review critically compares the epidemiology, clinical outcomes, and management strategies of HBV patients with concurrent HCV or MASLD, while addressing current research gaps and proposing directions for future investigations.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to correspondence on \"RAB25/GCN1 Signaling Promotes ER Stress to Mediate Alcohol-associated Liver Disease Progression\".","authors":"Seol Hee Park, Wonhyo Seo","doi":"10.3350/cmh.2025.1469","DOIUrl":"https://doi.org/10.3350/cmh.2025.1469","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dongman Yu, Yeongseok Hwang, Jin-Sung Ju, Subin Heo, Seon-Ok Kim, Sang Hyun Choi, Gi-Won Song, Jihyun An, Ju Hyun Shim
Background and aims: Various expanded criteria (EC) for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) have been proposed to avoid the narrow nature of the Milan criteria (MC). To investigate which EC predicts more favorable outcomes in terms of overall survival (OS) and recurrence-free survival (RFS), we conducted a network meta-analysis (NMA).
Methods: A database search was conducted on PubMed, Embase, and the Cochrane Library, to identify studies comparing OS and RFS between patients within the MC and those exceeding the MC but within the EC. Effect sizes were assessed using hazard ratios (HR), which were pooled in a random-effects NMA. The NMA results were validated in an in-house cohort of 1,008 LT recipients.
Results: Of 22,466 articles identified, 35 studies contained 45 pairwise comparisons and were included in the NMA along with 8 different EC. The use of UCSF (HR, 1.43; 95% CI, 1.19-1.71), Up-to-Seven (HR, 1.50; 95% CI, 1.15-1.97), and Hangzhou criteria (HR, 1.69; 95% CI, 1.11-2.57) yielded OS results inferior to the MC. The MC had the highest rank probability of being best followed by Metroticket 2.0 model and Asan criteria in terms of OS and RFS, respectively. Both Metroticket 2.0 and AFP model yielded more favorable HCC-specific mortality than other EC in the validation cohort.
Conclusion: Several EC, of which those of Metroticket 2.0 model were the best, yielded comparable outcomes to the MC. AFP-based EC such as Metroticket 2.0 and AFP model appeared to be useful in both the NMA and the validation cohort, suggesting a potential role in identifying selected low-risk patients beyond the MC.
{"title":"Network meta-analysis and validation study of expanded liver transplantation criteria for HCC: Significant role of AFP.","authors":"Dongman Yu, Yeongseok Hwang, Jin-Sung Ju, Subin Heo, Seon-Ok Kim, Sang Hyun Choi, Gi-Won Song, Jihyun An, Ju Hyun Shim","doi":"10.3350/cmh.2025.0986","DOIUrl":"https://doi.org/10.3350/cmh.2025.0986","url":null,"abstract":"<p><strong>Background and aims: </strong>Various expanded criteria (EC) for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) have been proposed to avoid the narrow nature of the Milan criteria (MC). To investigate which EC predicts more favorable outcomes in terms of overall survival (OS) and recurrence-free survival (RFS), we conducted a network meta-analysis (NMA).</p><p><strong>Methods: </strong>A database search was conducted on PubMed, Embase, and the Cochrane Library, to identify studies comparing OS and RFS between patients within the MC and those exceeding the MC but within the EC. Effect sizes were assessed using hazard ratios (HR), which were pooled in a random-effects NMA. The NMA results were validated in an in-house cohort of 1,008 LT recipients.</p><p><strong>Results: </strong>Of 22,466 articles identified, 35 studies contained 45 pairwise comparisons and were included in the NMA along with 8 different EC. The use of UCSF (HR, 1.43; 95% CI, 1.19-1.71), Up-to-Seven (HR, 1.50; 95% CI, 1.15-1.97), and Hangzhou criteria (HR, 1.69; 95% CI, 1.11-2.57) yielded OS results inferior to the MC. The MC had the highest rank probability of being best followed by Metroticket 2.0 model and Asan criteria in terms of OS and RFS, respectively. Both Metroticket 2.0 and AFP model yielded more favorable HCC-specific mortality than other EC in the validation cohort.</p><p><strong>Conclusion: </strong>Several EC, of which those of Metroticket 2.0 model were the best, yielded comparable outcomes to the MC. AFP-based EC such as Metroticket 2.0 and AFP model appeared to be useful in both the NMA and the validation cohort, suggesting a potential role in identifying selected low-risk patients beyond the MC.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aspirin for Hepatocellular Carcinoma Prevention in MASLD: How Far Are We Ready to Proceed? : Editorial on \"Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis\".","authors":"Yang-Hyun Baek","doi":"10.3350/cmh.2025.1482","DOIUrl":"https://doi.org/10.3350/cmh.2025.1482","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia Del Giudice
{"title":"Letter to the Editor on \"Evaluating Treatment Response Thresholds for Cost-Effective Treatment in Metabolic-Associated Steatotic Liver Disease\".","authors":"Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia Del Giudice","doi":"10.3350/cmh.2025.1417","DOIUrl":"10.3350/cmh.2025.1417","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号